Piermont Capital Management Inc. reduced its holdings in shares of Catalent (NYSE:CTLT) by 13.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,120 shares of the company’s stock after selling 1,680 shares during the period. Piermont Capital Management Inc.’s holdings in Catalent were worth $457,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in Catalent in the fourth quarter worth $242,000. Zeke Capital Advisors LLC purchased a new position in Catalent during the first quarter valued at $289,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Catalent by 45.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,325 shares of the company’s stock valued at $301,000 after buying an additional 2,282 shares during the period. Eagle Boston Investment Management Inc. lifted its position in Catalent by 40.0% during the fourth quarter. Eagle Boston Investment Management Inc. now owns 7,349 shares of the company’s stock valued at $306,000 after buying an additional 2,101 shares during the period. Finally, We Are One Seven LLC purchased a new position in Catalent during the fourth quarter valued at $343,000. Institutional investors and hedge funds own 99.28% of the company’s stock.
Several brokerages have commented on CTLT. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Thursday, May 10th. Royal Bank of Canada set a $48.00 price objective on Catalent and gave the company a “buy” rating in a research report on Monday, February 5th. Stephens downgraded Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Raymond James upgraded Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a report on Wednesday, March 21st. They noted that the move was a valuation call. Finally, UBS upgraded Catalent from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 21st. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $45.67.
Catalent opened at $40.08 on Wednesday, according to Marketbeat. Catalent has a one year low of $33.42 and a one year high of $47.87. The stock has a market capitalization of $5.39 billion, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 2.14 and a beta of 1.53. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, May 1st. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.35 by $0.06. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The company had revenue of $627.90 million during the quarter, compared to the consensus estimate of $610.47 million. During the same period last year, the company earned $0.38 EPS. Catalent’s revenue for the quarter was up 17.9% on a year-over-year basis. sell-side analysts expect that Catalent will post 1.55 EPS for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.